Core Viewpoint - The controlling shareholder of Shanghai Laishi Blood Products Co., Ltd., Haiyingkang (Qingdao) Medical Technology Co., Ltd., has successfully completed its shareholding increase plan, demonstrating confidence in the company's future development and long-term investment value [3][9]. Summary by Sections Shareholding Increase Plan - The plan was announced on May 22, 2025, with a commitment to increase shareholding by no less than RMB 250 million and no more than RMB 500 million within six months [3][7]. - The increase was executed through centralized bidding, with a total of 72,935,300 shares acquired, representing 1.10% of the total share capital, for approximately RMB 499.99 million (excluding transaction fees) [9]. Shareholder Information - Prior to the increase, Haiyingkang held 1,474,578,052 shares, accounting for 22.21% of the total share capital, and controlled an additional 437,069,656 shares through voting rights entrusted from Grifols, S.A., totaling 1,911,647,708 shares or 28.80% of the total [4]. Compliance and Commitments - The shareholding increase plan complies with relevant laws and regulations, ensuring that the company's shareholding structure remains within listing requirements [11]. - Haiyingkang has committed not to reduce its shareholding during the increase period and has adhered to regulations regarding insider trading and short-term trading [12].

Core Viewpoint - The controlling shareholder of Shanghai Pharmaceuticals, Shanghai Shiyuan Group, plans to increase its stake in the company through its wholly-owned subsidiary, Shanghai Shiyuan International Investment Co., Ltd. [2][3] Group 1: Basic Information of the Increasing Entity - The increasing entity, Shanghai Shiyuan International Investment Co., Ltd., is a wholly-owned subsidiary of Shanghai Shiyuan Group, which is the controlling shareholder of Shanghai Pharmaceuticals [2]. - After the recent purchase of 100,000 H-shares on September 15, 2025, Shanghai Shiyuan International now holds 300,538,000 H-shares, accounting for 8.104% of the total share capital of the company [2]. Group 2: Main Content of the Increasing Plan - The controlling shareholder, Shanghai Shiyuan Group, plans to increase its stake through Shanghai Shiyuan International by acquiring between 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [3]. - The increase will be executed through the Hong Kong Stock Exchange's centralized bidding system, with no fixed price range set for the purchases, allowing for flexibility based on market conditions [3]. Group 3: Other Relevant Information - The increasing plan complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Hong Kong Securities and Futures Commission's rules [7]. - The controlling shareholder and its subsidiaries commit not to reduce their holdings of the company's shares during the implementation of the increasing plan and for six months thereafter [7].

Core Viewpoint - The company, Meizhong Jiahua (02453), announced that its controlling shareholder, Concord Medical Services Holdings Limited (CCM), plans to increase its stake in the company within the next 12 months [1] Group 1: Shareholder Actions - CCM intends to acquire shares through its subsidiaries using its own funds in the open market [1] - The specific details of the share acquisition will be disclosed in accordance with regulations [1] Group 2: Strategic Intent - The share buyback plan aims to solidify CCM's controlling position and increase its ownership percentage [1] - This move is intended to convey a positive message to the market regarding CCM's confidence in the company's future prospects and long-term development [1]

Core Viewpoint - Concord Medical Services Holdings Limited (CCM) plans to increase its stake in the company within 12 months, signaling confidence in the company's future prospects [1] Group 1 - CCM will conduct the share buyback through its subsidiaries using its own funds in the open market [1] - The buyback aims to consolidate CCM's controlling position and increase its shareholding percentage [1] - The company will disclose specific buyback transactions in accordance with regulations [1]

增持计划旨在巩固CCM的控股地位，提高CCM的持股比例，并向市场传递控股股东对集团未来前景及 长远发展充满信心的积极信息。 格隆汇9月12日丨美中嘉和(02453.HK)发布公告，公司获公司控股股东Concord Medical Services Holdings Limited("CCM")告知，CCM计划于本公告起计12个月内增持公司股权。公司已获告知，为进行增持， CCM将透过其附属公司以自有资金于公开市场进行增持，具体增持交易将根据规则及时披露。 ...

Core Viewpoint - The company, Hubei Yihua, announced that its major shareholder, Yihua Group, has increased its stake in the company to bolster investor confidence and stabilize the stock price [1] Summary by Relevant Sections Shareholding Changes - As of the disclosure date, the total share capital of the company is 1,088,522,212 shares [1] - From June 10 to September 9, 2025, Yihua Group acquired an additional 12,499,000 shares, representing 1.15% of the current total share capital [1] - Following this acquisition, Yihua Group's total shareholding increased to 239,826,044 shares, accounting for 22.03% of the company [1] Purpose of Shareholding Increase - The increase in shareholding is aimed at enhancing investor confidence and maintaining stock price stability [1] - The acquisition will not lead to any changes in the distribution of shares that would affect the listing conditions or control of the company [1] Future Plans - Yihua Group had previously disclosed a share acquisition plan that remains incomplete and will continue to be executed [1]

Core Viewpoint - The controlling shareholder of Huaxi Biotechnology Co., Ltd. plans to increase its stake in the company, reflecting confidence in the company's future development and long-term investment value [2]. Summary by Sections Shareholder Buyback Plan - Huaxi Xinyu Investment Co., Ltd., the controlling shareholder, intends to increase its stake in Huaxi Biotechnology starting from August 8, 2025, for a period of six months, with a planned investment of no less than RMB 200 million and no more than RMB 300 million [2]. - The buyback will not exceed 1% of the company's total share capital, and the purchase price will not exceed RMB 70 per share [2]. Implementation Status - As of September 5, 2025, Huaxi Xinyu has acquired 3,496,931 shares, representing 0.73% of the total share capital, with a total expenditure of approximately RMB 200.68 million, surpassing the lower limit of the planned investment [2]. Risks Related to the Buyback Plan - There are potential risks that the buyback plan may not be implemented as expected due to changes in the capital market or other unpredictable factors [3][4].

Core Viewpoint - Guizhou Moutai has received a loan commitment from Agricultural Bank of China to support its controlling shareholder's stock buyback plan, with a loan amount not exceeding RMB 2.7 billion [2][4]. Group 1: Loan Commitment and Terms - The loan from Agricultural Bank of China is intended to support the stock buyback by Guizhou Moutai's controlling shareholder, Moutai Group, with a maximum amount of RMB 2.7 billion [2]. - The loan has a term of three years and is specifically designated for the purpose of increasing the company's stock holdings [2][4]. - The implementation of the loan is subject to the fulfillment of conditions recognized by Agricultural Bank and regulatory requirements [4]. Group 2: Stock Buyback Plan - Moutai Group plans to increase its shareholding in Guizhou Moutai between September 1, 2025, and February 28, 2026, with a total investment of no less than RMB 3 billion and no more than RMB 3.3 billion [4]. - The funding for the buyback will come from both self-owned and self-raised funds [4]. - There is no set price range for the buyback, allowing Moutai Group to act based on market conditions and the company's stock price [5]. Group 3: Recent Buyback Activity - On September 1, Moutai Group executed a buyback of 67,800 shares, representing 0.0054% of the total share capital, with an investment of approximately RMB 100 million [5]. - Moutai Group has committed not to reduce its shareholdings during the buyback period and the statutory timeframe [5].

Group 1 - The controlling shareholder, Dongyang Huasheng, plans to increase its stake in the company between May 7, 2025, and within six months, with an investment amount not less than 100 million and not exceeding 200 million [1] - The increase in shareholding has been delayed due to the company's ongoing plans to issue shares for asset acquisition [1] - Dongyang Huasheng has received a loan commitment letter from CITIC Bank Xiamen Branch, promising a maximum of 90 million for a period not exceeding 36 months to support this share purchase [1]

Core Viewpoint - China Three Gorges Corporation plans to increase its stake in China Yangtze Power Co., Ltd. by investing between RMB 4 billion and RMB 8 billion over the next 12 months, reflecting confidence in the company's future development [1] Group 1: Shareholding Information - The controlling shareholder, China Three Gorges Corporation, holds 10,474,432,302 shares, representing 42.81% of the total share capital before the planned increase [1] - The total shareholding of China Three Gorges Corporation and its concerted actions amounts to 12,864,812,941 shares, or 52.58% of the total share capital [1] Group 2: Implementation Progress - As of September 4, 2025, China Three Gorges Corporation has acquired a total of 41,147,100 shares through centralized bidding, with an investment amounting to RMB 1,164.4978 million [1] - The planned period for the share increase is from August 23, 2025, to August 21, 2026 [1] Group 3: Risks Related to the Increase Plan - The implementation of the increase plan may face risks due to changes in capital market conditions or other unpredictable factors [1] - The announcement does not indicate any changes in the controlling shareholder or actual controller as a result of this increase [2]